BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Forest Laboratories, Inc. (FRX) Receives Notification Of ANDA Filing For A Generic Equivalent Of Lexapro


10/19/2005 5:10:56 PM

NEW YORK, April 16 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. , announced today that it had received notification from Alphapharm Pty. Ltd. that it has filed an Abbreviated New Drug Application (ANDA) with a Paragraph IV Certification for a generic equivalent to Lexapro(R).

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

Howard Solomon, Chairman and Chief Executive Officer said, "We believe our patents on Lexapro are valid and strong patents and we therefore do not expect a generic product to be available until at least after the expiration of our substance patent, including patent extension, which will be in 2011. The early filing of ANDAs against well patented products by generic companies has become standard practice."

Except for the historical information contained herein, this release contains "forward-looking statements" within the meaning of the Private Securities Reform Act of 1995. These statements are subject to risks and uncertainties that affect our business, including risk factors listed from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2003 and Quarterly Report on Form 10-Q for the period ended June 30, 2003, September 30, 2003, and December 31, 2003. Actual results may differ materially from those projected.

Photo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

Forest Laboratories, Inc.

CONTACT: Charles E. Triano, Vice President, Investor Relations of ForestLaboratories, Inc., +1-212-224-6714, or charles.triano@frx.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES